Table 2. . Linear regression of SLCO1B1 polymorphisms on estrogen plasma concentrations prior to aromatase inhibitor initiation.
| SNP | Estrogen | Univariate analysis (N = 438) | Multivariable model† | ||||
|---|---|---|---|---|---|---|---|
| Concentration change per variant allele | 95% CI | p-value | Concentration change per variant allele | 95% CI | p-value | ||
| SLCO1B1*5 | E1 | 2% | -10–16 | 0.76 | |||
| E1S | 51% | 29–76 | <0.001 | 59% | 35–86 | <0.0001 | |
| E2 | 6% | -11–26 | 0.51 | ||||
| rs10841753 | E1 | -7% | -17–5 | 0.25 | |||
| E1S | -20% | -31 to -8 | 0.002 | -19% | -30 to -6 | 0.004 | |
| E2 | -5% | -19–11 | 0.48 | ||||
†
Corrected for age, BMI, smoking status, prior tamoxifen therapy and prior hormone replacement therapy.
E1: Estrone; E1S: Estrone sulfate; E2: Estradiol.